Phospho-GRIN1 (S897) Antibody

Basic Research Questions

• What is Phospho-GRIN1 (S897) and why is it important in neuroscience research?

  Phospho-GRIN1 (S897) refers to the phosphorylated state of the GRIN1 protein (also known as NMDAR1, NMDAζ1, or N-methyl-D-aspartate receptor subunit NR1) at the serine 897 position. GRIN1 is a critical subunit of N-methyl-D-aspartate receptors (NMDARs), which function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent inhibition by Mg²⁺ .

  Phosphorylation at S897 is particularly significant as it plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition, and learning . Studies have shown that phosphorylation of the NR1 subunit at S897 is markedly reduced in schizophrenia patients, highlighting its potential role in neuropsychiatric disorders .

• What species reactivity do these antibodies typically demonstrate?

  Most commercially available Phospho-GRIN1 (S897) antibodies demonstrate reactivity across the following species:

  • Human

  • Mouse

  • Rat

  Some antibodies may also have predicted reactivity with other species such as pig, bovine, horse, dog, chicken, and Xenopus, though these would require validation for specific experiments . The antibodies are typically raised in rabbits using synthetic phosphopeptides derived from human NMDAζ1 around the phosphorylation site of S897 .

Advanced Research Questions

• How does phosphorylation at S897 affect NMDAR function and neuronal signaling?

  Phosphorylation of GRIN1 at S897 significantly impacts NMDAR function in several ways:

  • Synaptic Incorporation: Preventing NR1 S897 phosphorylation causes severe impairment in synaptic NMDAR function. Studies with S897A mutant mice (where serine is replaced with alanine to prevent phosphorylation) showed a significant decrease in NR1 protein levels specifically in the synaptic fraction, while total brain homogenate levels remained unchanged .

  • AMPAR Trafficking: NR1 S897 phosphorylation is crucial for driving GluR1-containing AMPARs into synapses during synaptic plasticity. S897A mutant mice displayed significantly reduced GluR1 protein levels in the synaptic fraction and markedly reduced GluR1 immunoreactivity in the PSD region of dendritic spines .

  • Long-Term Potentiation (LTP): S897 phosphorylation is essential for LTP in Schafer collateral–CA1 synapses. S897A mutant mice showed impaired LTP, indicating that this phosphorylation site is critical for synaptic plasticity mechanisms underlying learning and memory .

  • Sensorimotor Gating: NR1 S897 phosphorylation plays a critical role in regulating neural circuitry underlying sensorimotor gating. S897A mutant mice exhibited significantly decreased prepulse inhibition (PPI), a measure of sensorimotor gating that is also impaired in schizophrenia patients .

• What experimental controls are essential when using Phospho-GRIN1 (S897) antibodies?

  When designing experiments with Phospho-GRIN1 (S897) antibodies, the following controls are essential:

  • Phosphorylation-Deficient Mutants: Using S897A mutants (where serine is replaced with alanine) serves as an excellent negative control to verify antibody specificity for phosphorylated S897 .

  • Phosphatase Treatment: Treating samples with phosphatases to remove phosphorylation can confirm that the antibody specifically recognizes the phosphorylated form.

  • Total GRIN1 Antibody: Using an antibody that detects GRIN1 regardless of phosphorylation status allows normalization and comparison of phosphorylation levels relative to total protein expression .

  • Peptide Competition Assay: Pre-incubating the antibody with phosphorylated peptide containing the S897 site should block specific binding and reduce signal.

  • Positive Controls: Include samples known to have high levels of S897 phosphorylation, such as neuronal cultures treated with PKA activators, as PKA is known to phosphorylate NR1 at S897 .

• How can researchers distinguish between phosphorylation at S897 and other phosphorylation sites on GRIN1?

  GRIN1 has multiple phosphorylation sites, including S890, S896, and S897, which can confound research if not properly distinguished:

  • Site-Specific Antibodies: Use antibodies specifically validated for each phosphorylation site. For example, antibodies targeting phospho-S890, phospho-S896, and phospho-S897 are commercially available .

  • Mutant Constructs: Utilize mutant constructs where specific serine residues are replaced with alanine or aspartic acid. As demonstrated in research, Grin2A mutants with phosphorylation sites mutated to alanine (SA; phospho-deficient) or aspartic acid (SD; phospho-mimetic) can help determine the role of specific phosphorylation sites .

  • Mass Spectrometry: For definitive identification, use phospho-proteomics approaches with mass spectrometry to map specific phosphorylation sites on the protein.

  • Functional Assays: Different phosphorylation sites may affect receptor function differently. For example, S897 phosphorylation particularly affects synaptic incorporation and AMPAR trafficking .

• What is the relationship between GRIN1 S897 phosphorylation and neuropsychiatric disorders?

  Several lines of evidence connect GRIN1 S897 phosphorylation with neuropsychiatric disorders:

  • Schizophrenia: Phosphorylation of the NR1 subunit at S897 is markedly reduced in schizophrenia patients . The S897A NR1 phosphomutant mice exhibit sensorimotor gating deficits, particularly impaired prepulse inhibition (PPI), which parallels observations in schizophrenia patients.

  • NMDAR Hypofunction Hypothesis: Reduced NMDAR function, such as that caused by genetic deficits or pharmacological treatments, may lead to inefficient phosphorylation of NR1 at S897, which further impairs NMDAR function in a positive-feedback-like mechanism. This results in impairments in synaptic function and plasticity, and abnormal behaviors .

  • Signaling Pathway Involvement: Since NR1 S897 is phosphorylated by PKA, changes in PKA pathway or calcineurin (a phosphatase) activity could lead to altered S897 phosphorylation. Both PKA pathway and calcineurin have been linked to schizophrenia .

  • Therapeutic Implications: Understanding the role of GRIN1 S897 phosphorylation in neuropsychiatric disorders may provide insights for therapeutic development. For example, strategies targeting antibody turnover have shown efficacy in proof-of-concept studies for receptor-related disorders .

• What methodological approaches can optimize Western blot detection of phospho-GRIN1 (S897)?

  To optimize Western blot detection of phospho-GRIN1 (S897), researchers should consider:

  • Sample Preparation: Use fresh tissue samples with phosphatase inhibitors (phosphatase inhibitor mixtures I and II) to prevent dephosphorylation during extraction . Homogenize tissues in ice-cold lysate buffer containing protease inhibitors.

  • Protein Fractionation: Consider separating synaptic membrane-associated proteins by biochemical fractionation, especially when studying synaptic incorporation of NMDARs .

  • Loading Controls: Use appropriate loading controls such as PSD-95 for synaptic fractions or total GRIN1 for normalization.

  • Antibody Dilution: For Western blot applications, use dilutions ranging from 1:500 to 1:2000 of phospho-GRIN1 (S897) antibody .

  • Detection System: Use a chemiluminescence system followed by autoradiography for sensitive detection .

  • Membrane Optimization: Use 4-12% gradient Bis-Tris gels for optimal separation of the approximately 120 kDa NR1 subunit .

  • Signal Verification: Confirm specificity by comparing with phosphorylation-deficient mutants or phosphatase-treated samples.

• How should researchers design experiments to investigate the functional consequences of S897 phosphorylation?

  To investigate functional consequences of S897 phosphorylation:

  1. Genetic Approaches:

     • Generate phospho-mutant models (S897A for phospho-deficient or S897D for phospho-mimetic) using knock-in strategies or viral expression systems .

     • Use Cre-loxP systems for cell-type or region-specific manipulation of GRIN1 phosphorylation.

  2. Electrophysiological Measurements:

     • Assess NMDAR-mediated synaptic transmission in wild-type versus S897A mutant preparations.

     • Examine long-term potentiation (LTP) and other forms of synaptic plasticity dependent on NMDAR function.

     • Evaluate spike-timing-dependent plasticity with various pairing intervals .

  3. Behavioral Assays:

     • Test prepulse inhibition (PPI) as a measure of sensorimotor gating.

     • Examine learning and memory behaviors, particularly those dependent on hippocampal function.

     • Assess behaviors relevant to neuropsychiatric disorders such as schizophrenia .

  4. Molecular Analysis:

     • Perform phosphoproteomic analysis to identify downstream signaling changes.

     • Investigate protein-protein interactions affected by S897 phosphorylation status.

     • Examine effects on receptor trafficking, surface expression, and synaptic localization .

• What role does S897 phosphorylation play in alternative splicing regulation of GRIN1?

  The relationship between S897 phosphorylation and alternative splicing of GRIN1 involves complex regulatory mechanisms:

  • Splice Variants and Phosphorylation: GRIN1 undergoes alternative splicing, producing different variants including those with the C1, C2, C2', and N1 splice cassettes . The phosphorylation at S897 occurs in the C-terminal region, which can be affected by alternative splicing.

  • Functional Diversity: Different splice variants may exhibit differential phosphorylation patterns or responses to kinases/phosphatases. For example, Western blot analysis has shown differential antibody recognition between NR1 subunits containing different splice variants (C2 only, C1+C2', or N1+C2') .

  • Developmental and Tissue-Specific Regulation: Splicing of the CI cassette exon of NMDARI (GRIN1) pre-mRNA is tissue- and developmental stage-specific in rat brain . This may interact with phosphorylation patterns to provide additional layers of functional regulation.

  • Experimental Approaches: To study the relationship between splicing and phosphorylation:

    1. Use antibodies specific to different splice variants (like the N1 splice variant antibody)

    2. Combine with phospho-specific antibodies to determine how phosphorylation varies across splice variants

    3. Create constructs with specific splice variants and mutations at phosphorylation sites

    4. Perform RT-PCR analysis for validation of cassette exons in conjunction with phosphorylation status assessment

• How does phosphorylation at S897 interact with other post-translational modifications of NMDA receptors?

  Phosphorylation at S897 interacts with other post-translational modifications in complex ways:

  • Multiple Phosphorylation Sites: GRIN1 contains multiple phosphorylation sites (S890, S896, S897) that can influence each other. For example, while S897 phosphorylation is critical for synaptic incorporation, other phosphorylation events at S890 or S896 may have distinct or overlapping functions .

  • Kinase/Phosphatase Balance: PKA phosphorylates NR1 at S897, while phosphatases like calcineurin (PP2B) can dephosphorylate this site. The balance between these activities determines the phosphorylation state and subsequent receptor function .

  • Ubiquitination and Phosphorylation: Recent research on phospho-ubiquitin suggests potential crosstalk between phosphorylation and ubiquitination pathways that might affect receptor trafficking and degradation .

  • Experimental Approaches:

    1. Use phospho-deficient and phospho-mimetic mutations at multiple sites to study interactions

    2. Apply specific kinase activators or inhibitors (PKA activators, FK506 for PP2B inhibition)

    3. Employ phosphoproteomics to examine global changes in phosphorylation patterns

    4. Analyze effects on receptor trafficking, surface expression, and channel properties

  • Therapeutic Relevance: Understanding the interaction between different post-translational modifications could provide novel therapeutic targets for neuropsychiatric disorders associated with NMDAR dysfunction .